Search research articles
Contact Us
Filters
Showing results (191-200 of 205) with videos related to
Page
of 21
Sort By:
Annals of Epidemiology
|
February 1, 1991
The Cardiovascular Health Study: design and rationale
L P Fried, N O Borhani, P Enright, et al.
Circulation
|
October 1, 1994
Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group
C D Furberg, H P Adams, W B Applegate, et al.
Hypertension (Dallas, Tex. : 1979)
|
March 1, 1991
Systolic Hypertension in the Elderly Program (SHEP). Part 1: Rationale and design
N O Borhani, W B Applegate, J A Cutler, et al.
Clinical and Experimental Hypertension. Part A, Theory and Practice
|
January 1, 1989
The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group
J L Probstfield, W B Applegate, N O Borhani, et al.
Stroke
|
February 1, 1996
Thickening of the carotid wall. A marker for atherosclerosis in the elderly? Cardiovascular Health Study Collaborative Research Group
D H O'Leary, J F Polak, R A Kronmal, et al.
Stroke
|
January 1, 1989
Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) pilot study
H M Perry, W M Smith, R H McDonald, et al.
Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension
|
December 1, 1986
Systolic Hypertension in the Elderly Program, Pilot Study (SHEP-PS): morbidity and mortality experience
H M Perry, R H McDonald, S B Hulley, et al.
Archives of Internal Medicine
|
January 9, 2001
Antihypertensive drug therapies and the risk of ischemic stroke
O H Klungel, S R Heckbert, W T Longstreth, et al.
The New England Journal of Medicine
|
August 24, 2000
Effects of estrogen replacement on the progression of coronary-artery atherosclerosis
D M Herrington, D M Reboussin, K B Brosnihan, et al.
JAMA
|
August 27, 1999
Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease
B M Psaty, N S Weiss, C D Furberg, et al.
Page
of 21
Search research articles
Search
Showing results (191-200 of 205) with videos related to
Sort By:
Page
of 21
Annals of Epidemiology
|
February 1, 1991
The Cardiovascular Health Study: design and rationale
L P Fried, N O Borhani, P Enright, et al.
Circulation
|
October 1, 1994
Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group
C D Furberg, H P Adams, W B Applegate, et al.
Hypertension (Dallas, Tex. : 1979)
|
March 1, 1991
Systolic Hypertension in the Elderly Program (SHEP). Part 1: Rationale and design
N O Borhani, W B Applegate, J A Cutler, et al.
Clinical and Experimental Hypertension. Part A, Theory and Practice
|
January 1, 1989
The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group
J L Probstfield, W B Applegate, N O Borhani, et al.
Stroke
|
February 1, 1996
Thickening of the carotid wall. A marker for atherosclerosis in the elderly? Cardiovascular Health Study Collaborative Research Group
D H O'Leary, J F Polak, R A Kronmal, et al.
Stroke
|
January 1, 1989
Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) pilot study
H M Perry, W M Smith, R H McDonald, et al.
Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension
|
December 1, 1986
Systolic Hypertension in the Elderly Program, Pilot Study (SHEP-PS): morbidity and mortality experience
H M Perry, R H McDonald, S B Hulley, et al.
Archives of Internal Medicine
|
January 9, 2001
Antihypertensive drug therapies and the risk of ischemic stroke
O H Klungel, S R Heckbert, W T Longstreth, et al.
The New England Journal of Medicine
|
August 24, 2000
Effects of estrogen replacement on the progression of coronary-artery atherosclerosis
D M Herrington, D M Reboussin, K B Brosnihan, et al.
JAMA
|
August 27, 1999
Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease
B M Psaty, N S Weiss, C D Furberg, et al.
Page
of 21